Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by jammer4444on Jul 30, 2017 12:12pm
130 Views
Post# 26526488

RE:ADK ... Google ... Perception and Trust !

RE:ADK ... Google ... Perception and Trust !Google violating privacy rules is nothing new..  But something investors might be curious to learn is that another competitor, IDx has partnered with IBM Watson, and is filing for FDA approval:

IDx, an early-stage medical device company focused on developing software-based algorithms that can identify disease in medical images is currently conducting an FDA clinical trial to obtain clearance for its first product, IDx-DR by the end of summer 2017. IDx-DR is a screening solution for diabetic retinopathy. IDx also has algorithms in development for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk. 

https://hitconsultant.net/2017/07/06/new-ai-device-diabetes-eye-screening/

Today IBM (NYSE: IBM) Watson Health and IDx announced a five-year strategic alliance to advance global eye health through cognitive computing applications. This announcement comes shortly after IBM announced that IDx joined the IBM Watson Medical Imaging Collaborative, which includes 24 healthcare leaders worldwide.

 

The partnership leverages more than a decade of IDx's medical image analysis work and IBM's global reach, and aims to help patients with serious eye conditions.  As part of the alliance, IBM Watson Health intends to distribute IDx's automated diabetic retinopathy (DR) screening solution, IDx-DR, in the 31 countries that comprise the European Economic Area.  This distribution may be expanded to Australia, Canada, and the United States pending regulatory approval.

https://www.eyediagnosis.net/single-post/2017/03/08/IBM-WH-OEM

Bullboard Posts